Literature DB >> 9477097

The expression of multidrug resistance protein in human gastrointestinal tract carcinomas.

Y Takebayashi1, S Akiyama, S Natsugoe, S Hokita, K Niwa, M Kitazono, T Sumizawa, A Tani, T Furukawa, T Aikou.   

Abstract

BACKGROUND: Multidrug resistance protein (MRP) is a membrane phosphoglycoprotein with an Mr of 190,000 that is involved in the non-P-glycoprotein mediated multidrug resistance of human tumor cells. The aim of this study was to determine the clinicopathologic relevance of MRP expression in human gastrointestinal tract carcinomas.
METHODS: The authors prepared a rabbit antiserum against MRP that does not cross-react with P-glycoprotein and retrospectively examined the expression of MRP in 86 squamous cell carcinomas of the esophagus, 103 adenocarcinomas of the stomach, and 139 colorectal adenocarcinomas by immunohistochemistry. None of the patients in this study had received prior chemotherapy.
RESULTS: The proportion of MRP positive samples in the squamous cell carcinomas of the esophagus (62.8%, 54 of 86) was significantly higher than that in the adenocarcinomas of the stomach (34.1%, 35 of 103) and the colorectal adenocarcinomas (40.3%, 56 of 139) (P <0.01). The proportion of MRP positivity in the well-differentiated carcinomas was significantly higher than that in moderately or poorly differentiated carcinomas. MRP expression was independent of gender, lymph node metastasis, and tumor progression.
CONCLUSIONS: These data indicate that the expression of MRP is correlated with the differentiation of carcinoma cells in the gastrointestinal tract and may be involved in the intrinsic drug resistance of well-differentiated squamous cell carcinoma of the esophagus.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9477097

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

Review 1.  How important are gender differences in pharmacokinetics?

Authors:  Bernd Meibohm; Ingrid Beierle; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  Portrait of multifaceted transporter, the multidrug resistance-associated protein 1 (MRP1/ABCC1).

Authors:  Eva Bakos; László Homolya
Journal:  Pflugers Arch       Date:  2006-12-23       Impact factor: 3.657

Review 3.  Development of multidrug-resistance convertors: sense or nonsense?

Authors:  L van Zuylen; K Nooter; A Sparreboom; J Verweij
Journal:  Invest New Drugs       Date:  2000-08       Impact factor: 3.850

Review 4.  Resistance mechanisms of gastrointestinal cancers: why does conventional chemotherapy fail?

Authors:  F Gieseler; P Rudolph; G Kloeppel; U R Foelsch
Journal:  Int J Colorectal Dis       Date:  2003-05-28       Impact factor: 2.571

5.  Multidrug resistance in primary tumors and metastases in patients with esophageal squamous cell carcinoma.

Authors:  Fang Qiang; Ren Guangguo; Han Yongtao; Dong Dandan; Yang Hong
Journal:  Pathol Oncol Res       Date:  2013-03-19       Impact factor: 3.201

6.  Decreased functional activity of multidrug resistance protein in primary colorectal cancer.

Authors:  Tamás Micsik; András Lőrincz; Tamás Mersich; Zsolt Baranyai; István Besznyák; Kristóf Dede; Attila Zaránd; Ferenc Jakab; László Krecsák Szöllösi; György Kéri; Richard Schwab; István Peták
Journal:  Diagn Pathol       Date:  2015-04-16       Impact factor: 2.644

7.  How difficult is the validation of clinical biomarkers?

Authors:  Jan Voskuil
Journal:  F1000Res       Date:  2015-04-28

8.  Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection.

Authors:  J-H Choi; H-Y Lim; H J Joo; H S Kim; J W Yi; H C Kim; Y K Cho; M W Kim; K B Lee
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

Review 9.  ABC Transporters and Their Role in the Neoadjuvant Treatment of Esophageal Cancer.

Authors:  David Vrana; Viktor Hlavac; Veronika Brynychova; Radka Vaclavikova; Cestmir Neoral; Jiri Vrba; Rene Aujesky; Marcel Matzenauer; Bohuslav Melichar; Pavel Soucek
Journal:  Int J Mol Sci       Date:  2018-03-15       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.